The collaboration will leverage hyperscale datasets, machine learning, and advanced computation to identify high-value, genetically validated drug targets and discover antibodies. Empirico will use its precision insights platform, a human genetics-focused discovery platform, to select up to five targets. AbCellera will use its artificial intelligence-powered antibody discovery technology to search and analyze natural immune responses to identify antibodies with desired properties against the five selected targets.

Under that agreement, Empirico will have the rights to develop and commercialize novel antibodies resulting from the collaboration. AbCellera will receive research payments and is eligible to receive downstream clinical and commercial milestone payments and royalties on net sales of products from Empirico.

Financial details of the agreement were not disclosed.

AbCellera acquires Trianni for $90M
Artificial intelligence-powered biotech and drug discovery platform AbCellera has purchased Trianni for $90 million. The deal boosts AbCellera's...

AbCellera raises $105M to fund antibody drug development
Artificial intelligence-powered biotech and drug discovery platform AbCellera has closed a $105 million series B financing round to expand its capacity...

AbCellera partners with Lilly for antibody discovery
AbCellera Biologics has joined forces with Eli Lilly on a multiyear initiative to identify antibodies for up to nine therapeutic targets.